<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sorbitol: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sorbitol: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sorbitol: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="12125" href="/d/html/12125.html" rel="external">see "Sorbitol: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12801" href="/d/html/12801.html" rel="external">see "Sorbitol: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F222443"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Genitourinary Irrigant;</li>
<li>
                        Laxative, Osmotic</li></ul></div>
<div class="block doa drugH1Div" id="F222419"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="76dc8a96-2f09-40f6-b114-2b6c9ece3538">Hyperosmotic laxative</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperosmotic laxative (as single dose, at infrequent intervals):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 30 to 45 mL (as 70% solution).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rectal enema:</b> 120 mL as 25% to 30% solution.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9fba20d3-008d-4d9e-9e6a-b2c3a4772f35">Transurethral surgical procedures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Transurethral surgical procedures:</b>
<b>Irrigation:</b> 3% to 3.3% as transurethral surgical procedure irrigation; volume needed will vary with the nature and duration of the procedure.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990140"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Irrigation is contraindicated in patients with anuria.</p></div>
<div class="block doha drugH1Div" id="F50987460"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F222420"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F222433"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12801" href="/d/html/12801.html" rel="external">see "Sorbitol: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5cf5683d-351d-423d-a054-afa1e6798e5c">Constipation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Constipation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Sorbitol is also found in some juices (eg, pear, apple, prune) and fruits (especially pureed or dried peaches or prunes), which may be recommended for use in infants and children before utilizing pharmacologic therapy (Blackmer 2010; Bolia 2020; Loening-Baucke 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 70% solution: <b>Note:</b> Dietary sorbitol more commonly recommended:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;12 years: Limited data available: Oral: 1 to 3 mL/kg/day in divided doses once or twice daily; maximum daily dose 60 mL/<b>day</b> (Maqbool 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: Oral: 30 to 60 mL in divided doses once or twice daily; maximum daily dose: 60 mL/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Rectal enema: 25% to 30% solution:</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: Rectal: 120 mL once daily as needed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="936d2dd2-0d6f-4abd-bb68-ca27270fda64">Toxic ingestion, adjunct with charcoal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Toxic ingestion, adjunct with charcoal:</b> Children and Adolescents: Oral: 35% solution: 4.3 mL/kg; <b>Note:</b> Current guidelines recommend limiting use to a single dose administered with the initial charcoal dose of 1 g/kg (AACT/EAPCCT 2004).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51160238"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51160239"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F222396"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Edema</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Electrolyte depletion, hyperglycemia, hypovolemia, lactic acidosis</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Abdominal distress, diarrhea, nausea, vomiting, xerostomia</p></div>
<div class="block coi drugH1Div" id="F222409"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Anuria (for irrigation).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>OTC labeling:</b> When used for self-medication, do not use for longer than 7 days or when abdominal pain, nausea, or vomiting is present.</p></div>
<div class="block war drugH1Div" id="F222393"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fluid/electrolyte imbalance: Large volumes may result in fluid overload and/or electrolyte changes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiopulmonary disease: Use with caution in patients with severe cardiopulmonary disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes; may cause hyperglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fructose intolerance: Avoid use in patients with known or suspected fructose intolerance.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Unable to metabolize sorbitol: Use with caution in patients unable to metabolize sorbitol.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): Constipation: When used for self-medication (OTC), notify health care provider prior to use if sudden change in bowel habits has persisted over a period of 2 weeks or if taking mineral oil. Discontinue use and notify health care provider if rectal bleeding or unable to have a bowel movement after use.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878638"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Excessive amounts of sorbitol may cause hypernatremic dehydration in pediatric patients; use with caution in infants; other causes of constipation should be evaluated prior to initiating therapy.</p></div>
<div class="block foc drugH1Div" id="F222403"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Irrigation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 3% (3000 mL); 3.3% (2000 mL, 4000 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 70% (30 mL [DSC], 474 mL [DSC], 480 mL, 3840 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Rectal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 70% (473 mL)</p></div>
<div class="block geq drugH1Div" id="F222389"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F222411"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sorbitol Irrigation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3% (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sorbitol Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">70% (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Sorbitol Rectal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">70% (per mL): $0.01</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F57861985"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Irrigation:</b> For irrigation only; not for injection. Prior to use, may warm in overwrap to near body temperature in a water bath or oven heated to ≤45°C (≤113°F). Use with irrigation set; see manufacturer labeling for complete instructions on use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> May administer without regard to food.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rectal:</b> Administer as a prepared enema; a 25% to 30% solution may be made by diluting one part 70% sorbitol with 2.3 parts water.</p></div>
<div class="block admp drugH1Div" id="F56979554"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May administer without regard to food.</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal: Administer as a prepared enema.</p></div>
<div class="block use drugH1Div" id="F222406"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperosmotic laxative</b>
<b>: </b>Relief of occasional constipation and irregularity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Transurethral surgical procedures</b>
<b>: </b>Genitourinary irrigant in transurethral procedures requiring distension, irrigation, and lavage of the urinary bladder; lavage of indwelling catheters to maintain patency.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution may also be used as a pharmaceutical vehicle or sweetening agent.</p></div>
<div class="block cyt drugH1Div" id="F13300074"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6223042"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Calcium Polystyrene Sulfonate: Sorbitol may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of these agents may increase the risk for intestinal necrosis. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamiVUDine: Sorbitol may decrease the serum concentration of LamiVUDine.  Management: When possible, avoid chronic coadministration of sorbitol-containing solutions with lamivudine, but if this combination cannot be avoided, monitor patients more closely for possible therapeutic failure associated with decreased lamivudine exposure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Polystyrene Sulfonate: Sorbitol may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of these agents may increase the risk for intestinal necrosis. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F14079771"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted.</p></div>
<div class="block brc drugH1Div" id="F16571283"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">The manufacturer recommends that caution be exercised when administering sorbitol to breastfeeding patients.</p></div>
<div class="block mop drugH1Div" id="F222401"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for fluid overload and/or electrolyte disturbances following large volumes; GI distress (bloating, flatulence)</p></div>
<div class="block pha drugH1Div" id="F222392"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">A polyalcoholic sugar with osmotic cathartic actions</p></div>
<div class="block phk drugH1Div" id="F222408"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Rectal: 0.25-1 hour </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral, rectal: Poor </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Primarily hepatic to fructose</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038830"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Sorbitol Enema</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11342776">
<a name="11342776"></a>Abraham SC, Bhagavan BS, Lee LA, Rashid A, Wu TT. Upper gastrointestinal tract injury in patients receiving kayexalate (sodium polystyrene sulfonate) in sorbitol: clinical, endoscopic, and histopathologic findings. <i>Am J Surg Pathol</i>. 2001;25(5):637-644. doi:10.1097/00000478-200105000-00011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/11342776/pubmed" id="11342776" target="_blank">11342776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24759345">
<a name="24759345"></a>Albeldawi M, Gaur V, Weber L. Kayexalate-induced colonic ulcer. <i>GastroenterolRep (Oxf)</i>. 2014;2(3):235-236. doi:10.1093/gastro/gou011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/24759345/pubmed" id="24759345" target="_blank">24759345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15362590">
<a name="15362590"></a>American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists. Position Paper: Cathartics. <i>J Toxicol Clin Toxicol</i>. 2004;42(3):243-253.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/15362590/pubmed" id="15362590" target="_blank">15362590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10584586">
<a name="10584586"></a>American Academy of Clinical Toxicology and European Association of Poison Centres and Clinical Toxicologists. Position Statement and Practice Guidelines on the Use of Multi-dose Activated Charcoal in the Treatment of Acute Poisoning. <i>J Toxicol Clin Toxicol</i>.1999;37(6):731-751.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/10584586/pubmed" id="10584586" target="_blank">10584586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29311732">
<a name="29311732"></a>Bansal R, Abdu A, Arya V. Sodium polystyrene sulfonate in sorbitol-induced colonic ulcerations. <i>Am J Gastroenterol</i>. 2018;113(1):11. doi:10.1038/ajg.2017.367<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/29311732/pubmed" id="29311732" target="_blank">29311732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8688109">
<a name="8688109"></a>Bennett LN, Myers TF, Lambert GH. Cecal perforation associated with sodiumpolystyrene sulfonate-sorbitol enemas in a 650 gram infant with hyperkalemia. <i>Am J Perinatol</i>. 1996;13(3):167-170. doi:10.1055/s-2007-994318<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/8688109/pubmed" id="8688109" target="_blank">8688109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20971414">
<a name="20971414"></a>Blackmer AB, Farrington EA. Constipation in the pediatric patient: an overview and pharmacologic considerations. <i>J Pediatr Health Care</i>. 2010;24(6):385-399. doi:10.1016/j.pedhc.2010.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/20971414/pubmed" id="20971414" target="_blank">20971414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33197982">
<a name="33197982"></a>Bolia R, Safe M, Southwell BR, King SK, Oliver MR. Paediatric constipation for general paediatricians: review using a case-based and evidence-based approach. <i>J Paediatr Child Health.</i> 2020;56(11):1708-1718. doi:10.1111/jpc.14720<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/33197982/pubmed" id="33197982" target="_blank">33197982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29127125">
<a name="29127125"></a>Cerrud-Rodriguez RC, Alcaraz-Alvarez D, Chiong BB, Ahmed A. Vancomycin-resistant <i>Enterococcus faecium</i> bacteraemia as a complication of Kayexalate (sodium polystyrene sulfonate, SPS) in sorbitol-induced ischaemic colitis. <i>BMJ Case Rep</i>. 2017;2017:bcr2017221790. doi:10.1136/bcr-2017-221790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/29127125/pubmed" id="29127125" target="_blank">29127125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10832954">
<a name="10832954"></a>Dardik A, Moesinger RC, Efron G, Barbul A, Harrison MG. Acute abdomen with colonic necrosis induced by Kayexalate-sorbitol. <i>South Med J</i>. 2000;93(5):511-513.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/10832954/pubmed" id="10832954" target="_blank">10832954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34720839">
<a name="34720839"></a>Dasu N, Khalid Y, Dasu K, Joo L, Blair B. Sodium polystyrene sulfonate-induced gastric pneumatosis: a rare side effect. <i>Case Rep Gastroenterol</i>. 2021;15(3):885-890. doi:10.1159/000518929<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/34720839/pubmed" id="34720839" target="_blank">34720839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9395757">
<a name="9395757"></a>Gardiner GW. Kayexalate (sodium polystyrene sulphonate) in sorbitol associated with intestinal necrosis in uremic patients. <i>Can J Gastroenterol</i>. 1997;11(7):573-577. doi:10.1155/1997/370814<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/9395757/pubmed" id="9395757" target="_blank">9395757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1496969">
<a name="1496969"></a>Gerstman BB, Kirkman R, Platt R. Intestinal necrosis associated with postoperative orally administered sodium polystyrene sulfonate in sorbitol. <i>Am J Kidney Dis</i>. 1992;20(2):159-161. doi:10.1016/s0272-6386(12)80544-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/1496969/pubmed" id="1496969" target="_blank">1496969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27033844">
<a name="27033844"></a>Jacob SS, Parameswaran A, Parameswaran SA, Dhus U. Colitis induced by sodium polystyrene sulfonate in sorbitol: a report of six cases. <i>Indian J Gastroenterol</i>. 2016;35(2):139-142. doi:10.1007/s12664-016-0635-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/27033844/pubmed" id="27033844" target="_blank">27033844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3824154">
<a name="3824154"></a>Lillemoe KD, Romolo JL, Hamilton SR, Pennington LR, Burdick JF, Williams GM. Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbitol enemas: clinical and experimental support for the hypothesis. <i>Surgery</i>. 1987;101(3):267-272.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/3824154/pubmed" id="3824154" target="_blank">3824154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15756220">
<a name="15756220"></a>Loening-Baucke V. Prevalence, symptoms and outcome of constipation in infants and toddlers. <i>J Pediatr</i>. 2005;146(3):359-363. doi:10.1016/j.jpeds.2004.10.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/15756220/pubmed" id="15756220" target="_blank">15756220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Maqbool.1">
<a name="Maqbool.1"></a>Maqbool A, Liacouras C. Encopresis and functional constipation. In: Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020: chap 358.3.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19373153">
<a name="19373153"></a>McGowan CE, Saha S, Chu G, Resnick MB, Moss SF. Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol. <i>South Med J</i>. 2009;102(5):493-497. doi:10.1097/SMJ.0b013e31819e8978<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/19373153/pubmed" id="19373153" target="_blank">19373153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7595773">
<a name="7595773"></a>Milley JR, Jung AL. Hematochezia associated with the use of hypertonic sodium polystyrene sulfonate enemas in premature infants. <i>J Perinatol</i>. 1995;15(2):139-142.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/7595773/pubmed" id="7595773" target="_blank">7595773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8990142">
<a name="8990142"></a>Rashid A, Hamilton SR. Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: an under recognized condition. <i>Am J Surg Pathol</i>. 1997;21(1):60-69. doi:10.1097/00000478-199701000-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/8990142/pubmed" id="8990142" target="_blank">8990142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11493807">
<a name="11493807"></a>Rogers FB, Li SC. Acute colonic necrosis associated with sodium polystyrene sulfonate (Kayexalate) enemas in a critically ill patient: case report and review of the literature. <i>J Trauma</i>. 2001;51(2):395-397. doi:10.1097/00005373-200108000-00031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/11493807/pubmed" id="11493807" target="_blank">11493807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9214411">
<a name="9214411"></a>Roy-Chaudhury P, Meisels IS, Freedman S, Steinman TI, Steer M. Combined gastric and ileocecal toxicity (serpiginous ulcers) after oral kayexalate in sorbital [sic] therapy. <i>Am J Kidney Dis</i>. 1997;30(1):120-122. doi:10.1016/s0272-6386(97)90574-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/9214411/pubmed" id="9214411" target="_blank">9214411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8500380">
<a name="8500380"></a>Scott TR, Graham SM, Schweitzer EJ, Bartlett ST. Colonic necrosis following sodium polystyrene sulfonate (Kayexalate)-sorbitol enema in a renal transplant patient. Report of a case and review of the literature. <i>Dis Colon Rectum</i>. 1993;36(6):607-609. doi:10.1007/BF02049870<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/8500380/pubmed" id="8500380" target="_blank">8500380</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sodium polystyrene sulfonate powder for suspension [prescribing information]. Rahway. NJ: Sunrise Pharmaceutical, Inc; March 2020.</div>
</li>
<li>
<div class="reference">
                  Sorbitol 70% solution oral/rectal [prescribing information]. Huntsville, AL: Qualitest Pharmaceuticals Inc; February 2006.</div>
</li>
<li>
<div class="reference">
                  Sorbitol 70% solution rectal [prescribing information]. Brooklyn, NY: Geri-Care Pharmaceuticals Corp; December 2020.</div>
</li>
<li>
<div class="reference">
                  Sorbitol urologic irrigating solution 3% [prescribing information]. Deerfield, IL: Baxter Healthcare Corp; January 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19365182">
<a name="19365182"></a>Thomas A, James BR, Landsberg D. Colonic necrosis due to oral kayexalate in a critically-ill patient. <i>Am J Med Sci</i>. 2009;337(4):305-306. doi:10.1097/MAJ.0b013e31818dd715<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/19365182/pubmed" id="19365182" target="_blank">19365182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19826644">
<a name="19826644"></a>Trottier V, Drolet S, Morcos MW. Ileocolic perforation secondary to sodium polystyrene sulfonate in sorbitol use: a case report. <i>Can J Gastroenterol</i>. 2009;23(10):689-690. doi:10.1155/2009/986524<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/19826644/pubmed" id="19826644" target="_blank">19826644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27018102">
<a name="27018102"></a>Usta Y, Ramirez C, Dennert B. Image of the month: emphysematous gastritis and necrosis as a result of orally ingested sodium polystyrene sulfonate (Kayexalate) in sorbitol. <i>Am J Gastroenterol</i>. 2016;111(3):309. doi:10.1038/ajg.2015.250<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/27018102/pubmed" id="27018102" target="_blank">27018102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22683337">
<a name="22683337"></a>Watson MA, Baker TP, Nguyen A, et al. Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study. <i>Am J Kidney Dis</i>. 2012;60(3):409-416. doi:10.1053/j.ajkd.2012.04.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/22683337/pubmed" id="22683337" target="_blank">22683337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2817643">
<a name="2817643"></a>Wootton FT, Rhodes DF, Lee WM, Fitts CT. Colonic necrosis with Kayexalate-sorbitol enemas after renal transplantation. <i>Ann Intern Med</i>. 1989;111(11):947-949. doi:10.7326/0003-4819-111-11-947<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sorbitol-drug-information/abstract-text/2817643/pubmed" id="2817643" target="_blank">2817643</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9940 Version 149.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
